Nightingale has completed the acquisition of Finnish genetic testing company Negen
Company release, 3 February 2022 at 9:15 a.m. (EET) Nightingale Health Plc (“Nightingale”) announced on 18 January 2022, that it has agreed on an acquisition where it purchases all shares of Finnish genetic testing company Negen Oy (“Negen”). The transaction was subject to certain conditions, which have been fulfilled and the transaction has been completed. Negen will be reported as part of Nightingale Health Group as of 3 February 2022. For further information, please contact: Teemu Suna, CEOir@nightingalehealth.com Certified Advisor: Oaklins Merasco Ltd, tel. +358 9 6129